An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC)
Recent advances in the treatment of non-small cell lung cancer (NSCLC) have led to improvements in patient survival and quality of life. It is unclear whether molecular abnormalities associated with NSCLC cell survival, growth and proliferation are useful in predicting treatment benefit. We conducte...
Main Authors: | Cindy Quinton, Peter M. Ellis |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2011-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6694/3/3/3506/ |
Similar Items
-
Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective
by: Jing Zhu, et al.
Published: (2021-09-01) -
Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
by: Connor O’Leary, et al.
Published: (2020-09-01) -
Investigating the Efficacy of EGFR-TKIs and Anti-VEGFR Combination in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
by: Prashant Sakharkar, et al.
Published: (2024-03-01) -
EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway – A nationwide retrospective cohort study
by: Åslaug Helland, et al.
Published: (2022-01-01) -
Critical Appraisal of Gefitinib in the Treatment of Non-Small Cell Lung Cancer
by: Yung-Hung Luo, et al.
Published: (2015-09-01)